Files you have to refresh.
- Research
Assemble the evidence for each analysis.
- Between reviews
New developments leave the analysis behind.
- Next decision
Find and assess what changed before you decide.
Make your next strategic decision with current evidence.
Maven brings live intelligence to biopharma research: answer strategic questions, identify changes that matter, and keep selected project files current with source-linked edits.
NICE · London · HTA assessment March 2025 draft
Lecanemab costs extend beyond the drug.
Infusion delivery and monitoring affect the cost model.
Matched to your forecast
Choose a document format
market_forecast.xlsx Updated
B4ƒxInclude infusion delivery + monitoring
Treatment cost assumptionsLecanemab
ABC
1Cost componentModel assumptionEvidence
2Drug acquisitionIncludedBaseline
3Infusion deliveryNot includedAdd administration costs NICE¹
4MonitoringNot includedAdd MRI + follow-up NICE¹
Cost assumptionsSources+
Company logos
Move from static research to live intelligence.
Files Maven keeps current.
- Research
Start with global evidence already connected.
- Between reviews
Relevant changes reach your team and update selected working files.
- Next decision
Review what changed and decide what comes next.
01
Cover more ground.
02
Spend less time catching up.
03
Make more room for judgment.
See what changes your next decision.
Trial amendment
HTA guidance
Company update
Your team’s priorities
Does DAPA-MI still test the outcome in our thesis?
Matched to your watchExample signal
DAPA-MI changes its primary endpoint.
Previous primary endpointCV death or heart-failure hospitalization
Revised primary endpoint7-component cardiometabolic composite
The original cardiovascular endpoint is now secondary. Reassess the thesis against both outcomes.
View evidence
The registry records a February 2023 amendment prompted by a lower-than-expected blinded event rate. The primary endpoint became a hierarchical cardiometabolic composite assessed using a win-ratio analysis. The original cardiovascular endpoint became secondary. The registry results were published on 7 July 2024.
EU trial register · Amendment 23 Feb 2023Expand your view beyond the sources you can follow by hand.
Connect company updates, clinical evidence, regulatory decisions, and local market access to the assets and markets you follow.
Explore Live IntelligenceSources across the world
Source locations Highlighted: Companies
Signal detection
Regulatory
Nucala receives FDA approval for COPD (opens source in a new tab)GSK · 2025
Nucala · COPD
Clinical evidence
MATINEE results published for mepolizumab in COPD (opens source in a new tab)NEJM · 1 May 2025
Mepolizumab · COPD
Market access
Singapore publishes funding criteria for atopic dermatitis therapies (opens source in a new tab)ACE · 2 Jan 2024
Abrocitinib · Atopic dermatitis
Use Maven’s intelligence wherever your team works.
In the Maven platform
Research assets and maintain project files with Word, Excel, and PowerPoint downloads.
Explore the platformIn your AI assistant
Give your assistant Maven’s external intelligence alongside your internal knowledge and research methods.
Explore integrationsIn your own systems
Query structured biopharma data and access monitoring findings through the API, with webhook notifications when new signals are available.
Build with MavenLive intelligence for teams across biopharma.
Pharma & biotech
Bring current evidence into medical affairs, BD, CI, research, and strategy. Keep selected project files current as evidence changes.
For biopharma teamsLife sciences consultants
Apply your firm’s research methods to client questions and keep client deliverables current between readouts.
For consultantsInvestment firms
Pressure test your investment thesis and keep diligence memos current as new evidence challenges your assumptions.
For investment teams